Chesterfield, MO, United States of America

Muthunadar P Periasamy

This inventor holds 25 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents, primarily in Optical Imaging Agents. Top assignees: Mallinckrodt, Inc., Mallinckrodt Medical, Inc.. Active years: 1981-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Muthunadar P Periasamy. Retrieved from https://idiyas.com/inventor/muthunadar-p-periasamy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 48.0

 

 

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 418(Granted Patents)


Location History:

  • Creve Coeur, MO (US) (1981 - 1994)
  • Chesterfield, MO (US) (1994 - 2014)

Company Filing History:


Years Active: 1981-2014

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
X-Ray Contrast Media
Optical Contrast Agents
Physiological Function Monitoring
Tumor-Targeted Agents
Magnetic Resonance Imaging
Hydrophilic Compositions
Therapeutic Agents
Light Absorbing Compositions
Dual Photodiagnosis
Paramagnetic Complexes
Photodiagnosis
Dyes for Organ Function
25 patents (USPTO):Explore Patents

Title: Muthunadar P Periasamy: Innovating in Radiological Sciences

Introduction

Muthunadar P Periasamy, a prolific inventor based in Chesterfield, MO, has made significant contributions to the field of radiological sciences with a total of 25 patents to his name. His innovative work primarily focuses on the development of novel x-ray contrast media and optical contrast agents, advancing diagnostic imaging and therapeutic techniques.

Latest Patents

Among his latest patents, the invention of "Low Osmolar X-ray Contrast Media Formulations" stands out. This invention relates to nonionic x-ray contrast media formulations and includes radiological compositions that provide favorable properties for x-ray visualization. The injectable compositions consist of a pharmaceutically acceptable vehicle mixed with a triiodo-substituted benzene nucleus and a dimer of linked benzene nuclei.

Another notable patent is "Receptor-avid Exogenous Optical Contrast and Therapeutic Agents." This invention discloses cyanine dye bioconjugates that are useful for both diagnostic imaging and therapy. These compounds include a variety of cyanine dyes and are designed for better delivery to tumor cells compared to larger imaging agents. The incorporation of biocompatible organic solvents, such as dimethylsulfoxide, enhances the fluorescence of these compounds, making them versatile for various imaging and therapeutic applications, including endoscopic techniques and photoacoustic tumor imaging.

Career Highlights

Muthunadar has held pivotal roles in his career at Mallinckrodt, Inc. and Mallinckrodt Medical, Inc., where he has contributed to the advancement of medical technologies that improve patient outcomes. His work in these companies underscores his commitment to innovation in the medical field.

Collaborations

Throughout his career, Muthunadar has collaborated with esteemed colleagues such as Raghavan Rajagopalan and Samuel I. Achilefu. These collaborations have fostered the development of groundbreaking technologies that push the boundaries of diagnostic and therapeutic possibilities in medicine.

Conclusion

Muthunadar P Periasamy's extensive portfolio of patents and collaborative efforts exemplify his dedication to advancing radiological sciences. His pioneering inventions in x-ray contrast media formulations and optical diagnostic agents not only enhance imaging capabilities but also pave the way for more effective therapeutic strategies. As the medical field continues to evolve, Muthunadar’s contributions will undoubtedly leave a lasting impact.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…